reports
- Luis Arredondo
- Luis Arredondo
ALMIRALL: 4Q'25 RESULTS AND CHANGE OF T.P. TO UNDER REVISION (ANÁLISIS...
4Q'25 vs. 4Q'24 Results Sales: € 287.4 M (+11.4% vs. +10.7% BS(e) and +10.3% consensus); EBITDA: € 52.2 M (+3.6% vs. +4.0% BS(e) and +4.8% consensus); EBIT: € 14.3 M (-4.7% vs. +2.7% BS(e) and +14.0% consensus); Net Profit: € 7.1 M (+3450.0% vs. +3447.5% BS(e) and +3650.0% consensus); FY2025 vs. FY2024 Results Sales: € 1.108 Bn (+12.4% vs. +12.3% BS(e) and +12.1% consensus); EBITDA: € 232.9 M (+20.9% vs. +21.0% BS(e) and +21.2% consensus); EBIT: € 81.7 M (+52.7% vs. +54.8% BS(e) and +57.9% conse...
- Luis Arredondo
ALMIRALL: RDOS. 4T’25 Y CAMBIO DE P.O. BAJO REVISIÓN (ANÁLISIS BANCO S...
Rdos. 4T'25 vs 4T'24: Ventas: 287,4 M euros (+11,4% vs +10,7% BS(e) y +10,3% consenso); EBITDA: 52,2 M euros (+3,6% vs +4,0% BS(e) y +4,8% consenso); EBIT: 14,3 M euros (-4,7% vs +2,7% BS(e) y +14,0% consenso); BDI: 7,1 M euros (+3450,0% vs +3447,5% BS(e) y +3650,0% consenso); Rdos. 2025 vs 2024: Ventas: 1.108 M euros (+12,4% vs +12,3% BS(e) y +12,1% consenso); EBITDA: 232,9 M euros (+20,9% vs +21,0% BS(e) y +21,2% consenso); EBIT: 81,7 M euros (+52,7% vs +54,8% BS(e) y +57,9% consenso); BDI: 46...
- Research Department
INFORME DIARIO 23 FEBRERO + RDOS. ESPAÑA Y EUROPA. IDEAS DESTACADAS Y ...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ALMIRALL, INDRA SISTEMAS, SECTOR ELÉCTRICO Y ENERGÍA. EUROPA: VINCI. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 4T’25 que se publicarán en España y Europa en los próximos días. Tensión geopolítica en Irán en aumento Las bolsas europeas frenaron en la semana su avance, afectados en cierta medida, por el ...
- Research Department
IBERIAN DAILY 23 FEBRUARY + 4Q’25 RESULTS. HIGHLIGHTS AND REST OF PREV...
NEWS SUMMARY: ALMIRALL, ELECTRICITY SECTOR, INDRA. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 4Q’25 results to be released over the coming days in Spain. Geopolitical tension rising in Iran European stock markets halted their advance over the week, affected to some extent by the geopolitical noise regarding Iran and the US army’s preparation for a possible military incursi...
GSK: 1 director
A director at GSK bought 3,334 shares at 2,219p and the significance rating of the trade was 64/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close...
- Felix Fischer
- Haidje Rustau
- Jayanth Kandalam
- Peter Low
- Si Yong Ng
- Tanvi Arora
- Louis Boujard
- CFA
- Philippe Ourpatian
REL RELX PLC
CA CARREFOUR SA
BVI BUREAU VERITAS SA
ZURN ZURICH INSURANCE GROUP LTD
MF WENDEL SE
ALV ALLIANZ SE
KBC KBC GROUP N.V.
G ASSICURAZIONI GENERALI S.P.A.
BAYN BAYER AG
BA. BAE SYSTEMS PLC
GAS NATURGY ENERGY GROUP S.A.
ELI ELIA GROUP SA/NV
ASRNL ASR NEDERLAND NV
REC RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A.
INX IMCD N.V.
AD KONINKLIJKE AHOLD DELHAIZE N.V.
IHG INTERCONTINENTAL HOTELS GROUP PLC
STMN STRAUMANN HOLDING AG
PUIG PUIG BRANDS
AMRZ AMRIZE AG
AENA AENA S.M.E. SA
- Louis Boujard
- CFA
- Philippe Ourpatian
REL RELX PLC
CA CARREFOUR SA
BVI BUREAU VERITAS SA
ZURN ZURICH INSURANCE GROUP LTD
MF WENDEL SE
ALV ALLIANZ SE
KBC KBC GROUP N.V.
G ASSICURAZIONI GENERALI S.P.A.
BAYN BAYER AG
BA. BAE SYSTEMS PLC
GAS NATURGY ENERGY GROUP S.A.
ELI ELIA GROUP SA/NV
ASRNL ASR NEDERLAND NV
REC RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A.
INX IMCD N.V.
AD KONINKLIJKE AHOLD DELHAIZE N.V.
IHG INTERCONTINENTAL HOTELS GROUP PLC
STMN STRAUMANN HOLDING AG
PUIG PUIG BRANDS
AMRZ AMRIZE AG
AENA AENA S.M.E. SA
- Martial Descoutures
- Oussema Denguir
- Martial Descoutures
- Oussema Denguir
- Felix Fischer
- Haidje Rustau
- Jayanth Kandalam
- Si Yong Ng
- Tanvi Arora
Press release: Filing of the 2025 U.S. Form 20-F and French “Document ...
Press release: Filing of the 2025 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report Filing of the 2025 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report Paris, February 17, 2026. Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its “Document d’Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF). These documents are available on the company’s ...
Communiqué de presse : Dépôt du Document d’Enregistrement Universel 20...
Communiqué de presse : Dépôt du Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel, et du « Form 20-F » américain Dépôt du Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel, et du « Form 20-F » américain Paris, le 17 février 2026. Sanofi annonce avoir déposé son Document d’Enregistrement Universel 2025 contenant le Rapport Financier Annuel auprès de l’Autorité des marchés financiers (AMF) en France et son « Form 20-F » auprès de la « Securities and Exchange Commission » (SEC) aux Etats-Unis. Le rapport du Conseil d’administration ...
RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE ...
RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA(1) +14.5%, ADJUSTED NET INCOME(2) +14.5% Consolidated net revenue of € 2,618.4 million for full year 2025, +11.8% or +8.3% on a like-for-like basis(3) at constant exchange rates (CER)EBITDA(1) of € 991.1 million, +14.5%, margin on net revenue of 37.8% Adjusted net income(2) of € 651.1 million, +14.5%, margin on net revenue of 24.9%Net income of € 443.6 million, +6.5% Free cash flow(4) of € 558.8 million, +€ 23.7 million reflecting strong EBITDA partially offset by U.S. inventory build-up, higher intere...
RECORDATI ANNUNCIA SOLIDI RISULTATI PRELIMINARI PER L’ESERCIZIO 2025: ...
RECORDATI ANNUNCIA SOLIDI RISULTATI PRELIMINARI PER L’ESERCIZIO 2025: RICAVI +11,8%, EBITDA(1) +14,5%, UTILE NETTO RETTIFICATO(2) +14,5%; Ricavi netti consolidati per l’esercizio 2025 pari a € 2.618,4 milioni, +11,8% o +8,3% a perimetro omogeneo(3) e a cambi costantiEBITDA(1) pari a € 991,1 milioni, +14,5%, con un’incidenza sui ricavi netti del 37,8%Utile netto rettificato(2) pari a € 651,1 milioni, +14,5% con un’incidenza sui ricavi netti del 24,9%Utile netto pari a € 443,6 milioni, +6,5%Free cash flow(4) pari a € 558,8 milioni, +€ 23,7 milioni, grazie a un solido EBITDA, compensato in pa...
Press Release: Sanofi and Teva’s duvakitug phase 2b maintenance data d...
Press Release: Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of induction Duvakitug was well tolerated and safety was consistent with the induction studyFindings reinforce the potent...
Communiqué de presse : Les données de phase IIb de l’étude d’entretien...
Communiqué de presse : Les données de phase IIb de l’étude d’entretien sur le duvakitug de Sanofi et Teva ont démontré une efficacité durable cliniquement significative dans la colite ulcéreuse et la maladie de Crohn Les données de phase IIb de l’étude d’entretien sur le duvakitug de Sanofi et Teva ont démontré une efficacité durable cliniquement significative dans la colite ulcéreuse et la maladie de Crohn Dans l’étude de phase IIb RELIEVE UCCD LTE, le duvakitug a montré une efficacité robuste et durable pendant 44 semaines supplémentaires chez les patients atteints de CU et de MC qui ava...
- Carole Braudeau
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.